Contact UsInvestorsCareersMediaScienceContact Us
HomeScienceDeveloping New MedicinesPipeline

Pfizer Pipeline

Globally, our scientists are committed to transforming molecules into medicines in order to improve the lives of millions of people around the world.

In recent years, we have evaluated and improved our research and development (R&D) methods in order to deliver to patients a sustainable flow of novel medicines and vaccines. As a result, globally, as of 30th of January 2024, we had 31 Phase 3 clinical trials in progress.1

Source: Pfizer data on file.
Note: This Pfizer Pipeline Snapshot is updated 4 times a year.

Pfizer, as a global organisation, collaborates with scientists, technicians, regulatory professionals and business experts across the world, including those in the UK, to find and develop the next generation of innovative medicines for patients.

As part of our approach, we also work with other innovators across the health landscape including academic scientists, patient organisations, governments, other biopharmaceutical companies and healthcare professionals.

We focus our efforts in core areas where we are best positioned to develop medicines and vaccines for conditions with significant unmet need. This includes cardiovascular and metabolic disease, chronic inflammatory and autoimmune diseases, infectious diseases, oncology, pain, and rare diseases.

OUR SCIENCEClinical Trials

Clinical trials are an essential step in the medicine development process.


Developing New Medicines

Our medicines save and transform the lives of millions around the world every year, but developing them is a complicated process.


    1. Pfizer data on file. January 2024
    PP-UNP-GBR-8537 / March 2024
    Science Products Responsibility PartnershipsCareers Privacy Statement Terms of Use Contact UsSitemap Copyright © 2017-2024 Pfizer Limited. PP-UNP-GBR-8108 / January 2024. All rights reserved. Registered in England and Wales No. 526209. Registered office: Ramsgate Road, Sandwich, Kent CT13 9NJ. VAT No. GB201048427. This website is intended for the general public in the UK.